PI-1840

• Description :

  PI-1840 is a potent and selective chymotrypsin-like (CT-L) inhibitor for with an IC50 value of 27 nM. PI-1840 inhibits cell proliferation and arrest cell cycle at G2/M phase. PI-1840 induces apoptosis and induces autophagy. PI-1840 induces the accumulation of proteasome substrates p27, Bax, and IκB-α[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H317-H319

• Target :

  Apoptosis; Autophagy; Bcl-2 Family; Caspase; NF-κB; PARP; Proteasome

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; NF-κB

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/PI-1840.html

• Purity :

  98.78

• Solubility :

  DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

• Smiles :

  O=C(N(C(C)C)CC1=NC(C2=CC=CN=C2)=NO1)COC3=CC=C(CCC)C=C3

• Molecular Formula :

  C22H26N4O3

• Molecular Weight :

  394.47

• Precautions :

  P261-P264-P272-P280-P302+P352-P305+P351+P338-P362+P364-P501

• References & Citations :

  [1]Kazi A, et, al. Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity. J Biol Chem. 2014 Apr 25;289 (17) :11906-11915.|[2]Chen Y, et, al. Non covalent proteasome inhibitor PI 1840 induces apoptosis and autophagy in osteosarcoma cells. Oncol Rep. 2019 May;41 (5) :2803-2817.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1401223-22-0]